Dicerna Pharmaceuticals company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Take Private | Alive

Total Raised






About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Dicerna Pharmaceuticals Headquarter Location

480 Arsenal St Building 1, Suite 120

Watertown, Massachusetts, 02472,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Dicerna Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dicerna Pharmaceuticals is included in 4 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,750 items

Dicerna Pharmaceuticals Patents

Dicerna Pharmaceuticals has filed 72 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • MicroRNA
patents chart

Application Date

Grant Date


Related Topics




MicroRNA, RNA, Molecular biology, Hepatology, Gene expression


Application Date


Grant Date



Related Topics

MicroRNA, RNA, Molecular biology, Hepatology, Gene expression



Latest Dicerna Pharmaceuticals News

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

Mar 30, 2022

Boston, Massachusetts, UNITED STATES BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Jennifer Cormier as Senior Vice President, Clinical Operations and Dr. Jeffrey Foy as Vice President, Toxicology. Ms. Cormier brings over 15 years of experience in therapeutic and medical device development to the PepGen team, and in her new role will lead clinical operations across the company’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapeutics, including PGN-EDO51, PepGen’s clinical-stage product candidate for the treatment of Duchenne muscular dystrophy. With over 20 years of experience in the pharmaceutical industry, Dr. Foy brings deep expertise in the toxicology of oligonucleotide and peptide therapeutics to PepGen, and will facilitate the company’s efforts to discover, develop and translate EDO product candidates. “Jennifer and Jeff bring a wealth of experience in the development of transformative therapeutics to our team, and both will be instrumental in advancing our portfolio of EDO programs for patients with deep unmet need,” said James McArthur, Ph.D., President and Chief Executive Officer of PepGen. “Following Health Canada’s recent acceptance of our Clinical Trial Application (CTA) for PGN-EDO51, and the initiation of our first-in-human clinical trial for this product candidate expected in the next month, Jennifer and Jeff will play a critical role in enabling our clinical-stage operations, and in preparing our pipeline therapeutics for future clinical trials.” Ms. Cormier has led a number of clinical-stage programs across the course of her career, ranging from first-in-human trials through to post-marketing approval studies in a variety of therapeutic areas, including rare genetic diseases, women’s health, Parkinson’s disease, diabetes and obesity, and major depressive disorder. Prior to joining PepGen, Ms. Cormier served as Vice President of Clinical Operations at Relmada Therapeutics, where she was responsible for oversight and execution of late-phase clinical programs. She has also held leadership roles at Sojournix, Acorda Therapeutics, GI Dynamics and Shire. She earned her Bachelor of Science degree in Biology from the University of Massachusetts in Boston. Ms. Cormier added, “I am honored to be joining the PepGen team, which has a diversity of talent and expertise that is truly unique. PepGen’s leadership shares my own passion for developing therapies that have the potential to improve therapeutic outcomes for people living with rare diseases. Their purposeful focus on that mission is inspiring, and serves as a constant source of motivation as we drive our programs forward into clinical trials.” Dr. Foy previously served as the Executive Director of Toxicology at Dicerna Pharmaceuticals, where he designed and executed nonclinical safety pharmacology and toxicology studies for internal and partnered development assets. Prior to his time at Dicerna, he held various leadership positions at Celgene, where he worked across a number of therapeutic areas, including oncology, inflammation and immunology. Dr. Foy has made broad contributions to our understanding of the toxicology of oligonucleotide and peptide therapeutics, and his work has been cited in numerous peer-reviewed publications and presentations. He is a Diplomate of the American Board of Toxicology, a member of the Oligonucleotide Therapeutics Society, and Chair of the Oligonucleotide Safety Working Group. Dr. Foy received his Ph.D. in Toxicology from Northeastern University in Boston after obtaining his Bachelor of Science in Biological Sciences at the University of Vermont. “I am delighted to have joined such an amazing team at PepGen. Our programs have tremendous potential to make a meaningful impact in the lives of patients with rare neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, and I look forward to contributing to the continued progress of our EDO programs,” said Dr. Foy. About PepGen PepGen, Inc. is a biotechnology company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases. PepGen’s proprietary Enhanced Delivery Oligonucleotides (EDOs) are designed to target the underlying causes of rare diseases, such as Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), in a safe and effective manner. In preclinical studies, PepGen’s enhanced delivery peptides demonstrated highly effective cell penetration and delivery of therapeutic candidates to multiple tissue types, including cardiac tissue. PepGen was founded by leading neuromuscular and neurology researchers in Oxford and Cambridge, UK, and is backed by a strong syndicate of investors including RA Capital Management, Oxford Science Enterprises, and others. The company is headquartered in Boston, Mass. For more information, visit  www.pepgen.com or follow PepGen on  Twitter   and  LinkedIn . Media Contact

Dicerna Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Dicerna Pharmaceuticals Rank

  • When was Dicerna Pharmaceuticals founded?

    Dicerna Pharmaceuticals was founded in 2007.

  • Where is Dicerna Pharmaceuticals's headquarters?

    Dicerna Pharmaceuticals's headquarters is located at 480 Arsenal St, Watertown.

  • What is Dicerna Pharmaceuticals's latest funding round?

    Dicerna Pharmaceuticals's latest funding round is Take Private.

  • How much did Dicerna Pharmaceuticals raise?

    Dicerna Pharmaceuticals raised a total of $123.8M.

  • Who are Dicerna Pharmaceuticals's competitors?

    Competitors of Dicerna Pharmaceuticals include Sirnaomics, Oxford BioMedica, Cell Point, Agrisoma BioSciences, PhaseRx, KemPharm, Bar Harbor BioTechnology, Vascular Biogenics, Calibrant Biosystems, Advanced Cell Technology and 12 more.

You May Also Like

Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.


Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Agrisoma BioSciences

Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.


OrphageniX is a drug development company aiming to develop therapeutics for genetic diseases using advancements in "Gene Editing" technologies. OrpageniX will focus on the low volume, high margin specialty pharmaceutical niche area of "Orphan Diseases" which are protected under the Orphan Drug Act (ODA). Per the company, the OrphageniX technology can be used for diagnostics and research tools. Gene Editing uses the cell's innate repair mechanisms to repair mutations that result in genetic diseases. According to OrphaageniX, it is similar to gene therapy but avoids the risks associated with a viral vector. It works like anti-sense and RNAi, but is more efficient and permanent within the repaired cell because it changes the gene itself and not the transient message. The company states that it has major collaborations with Yale Medical School, Albert Einstein Medical Center and the University of Washington.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.